 |
 |
Targeted therapies can be developed against receptors, genes and proteins in cellular signaling pathways which support cancer cell growth. Targeted therapies have advantages over traditional chemotherapy in that they inhibit cancer cells but have low toxicity to normal cells and tissues thus avoiding the severe side effects common in traditional chemotherapy treatments of cancer. |
LymphoSign is developing a number of novel compounds discovered in the laboratory of Dr. Chaim Roifman at The Hospital for Sick Children, Toronto. These compounds inhibit abnormal cellular signalling specific to the growth of cancer cells. LymphoSign's lead drug candidate LS104 is nearing completion of pre-clinical testing and has shown great promise as a potential treatment of acute leukemias (ALL and AML) as well as other cancers. LS104 has demonstrated very low or no toxicity toward normal cells.
|
|
